Abstract 6275: Evaluation of FRα/TRPV6 expression in gynecological cancer

Abstract

Abstract Purpose:Folate Receptor Alpha (FRα) is highly expressed in multiple malignancies, including ovarian, NSCLC and breast cancer. Transient Receptor Potential Vanilloid 6(TRPV6) is upregulated in breast, ovarian and prostate cancer. However, there is no report on expression and correlation between expression of the two markers. Since both markers are highly expressed in ovarian cancer, it is of great interest to evaluate expression of FRα and TRPV6 in a panel of gynecological cancer, including those major subtypes. Method:We have collected 200+ FFPE samples achieved in pathology core at National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, including high grade and low grade serous ovarian cancer and clear cell ovarian cancer et al. Using validated IHC assays, expression of both FRα and TRPV6 are evaluated. Result:Various levels of FRα and TRPV6 express in different histological subtypes of ovarian cancer. High grade serous ovarian cancer expresses the highest levels of FOLR1, which is about 2.8 and 2 folds over that of low-grade ovarian cancer and that of clear cancer ovarian cancer, respectively. The highest levels of TRPV6 expression are observed in clear cell ovarian cancer, which is 2.6 and 1.6 folds over that observed in low grade ovarian cancer and that observed in high grade ovarian cancer, respectively. The two biomarker expression is overlapped in about 45% of all samples analyzed. A comparison of samples from patients with or without good response to neoadjuvant therapy reveals samples with poor responses tend to express higher levels of FRα than those with good responses do. Addition evaluation and analysis are still on-going. Conclusion: FRα and TRPV6 are highly express in gynecological cancer. Evaluation of their expression is of great value for molecularly-targeted therapies for those two targets and provide a precision medicine option for the clinical development for such drugs. Citation Format: Ning Li, Yifan Li, Wei Tan, Yan Teng, Baohua Huang, Lingying Wu. Evaluation of FRα/TRPV6 expression in gynecological cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6275.